Acute-on-chronic heart failure-related cardiogenic shock had a higher 30-day mortality risk than de novo presentation (55.9% vs 45.5%; adjusted HR 1.38; 95% CI 1.10-1.72; p=0.005).
Observational (n=1,030)
Yes
Does acute-on-chronic heart failure-related cardiogenic shock increase 30-day mortality compared to de novo heart failure-related cardiogenic shock in patients with HF-CS?
In patients with heart failure-related cardiogenic shock, an acute-on-chronic presentation is associated with significantly higher 30-day mortality compared to a de novo presentation.
Effect estimate: adjusted HR 1.38 (95% CI 1.10-1.72)
Absolute Event Rate: 55.9% vs 45.5%
p-value: p=0.005
AIMS: Heart failure-related cardiogenic shock (HF-CS) accounts for a significant proportion of CS cases. Whether patients with de novo HF and those with acute-on-chronic HF in CS differ in clinical characteristics and outcome remains unclear. The aim of this study was to evaluate differences in clinical presentation and mortality between patients with de novo and acute-on-chronic HF-CS. METHODS AND RESULTS: In this international observational study, patients with HF-CS from 16 tertiary care centres in five countries were enrolled between 2010 and 2021. To investigate differences in clinical presentation and 30-day mortality, adjusted logistic/Cox regression models were fitted. Patients (n = 1030) with HF-CS were analysed, of whom 486 (47.2%) presented with de novo HF-CS and 544 (52.8%) with acute-on-chronic HF-CS. Traditional markers of CS severity (e.g. blood pressure, heart rate and lactate) as well as use of treatments were comparable between groups. However, patients with acute-on-chronic HF-CS were more likely to have a higher CS severity and also a higher mortality risk, after adjusting for relevant confounders (de novo HF 45.5%, acute-on-chronic HF 55.9%, adjusted hazard ratio 1.38, 95% confidence interval 1.10-1.72, p = 0.005). CONCLUSION: In this large HF-CS cohort, acute-on-chronic HF-CS was associated with more severe CS and higher mortality risk compared to de novo HF-CS, although traditional markers of CS severity and use of treatments were comparable. These findings highlight the vast heterogeneity of patients with HF-CS, emphasize that HF chronicity is a relevant disease modifier in CS, and indicate that future clinical trials should account for this.
Sundermeyer et al. (Wed,) conducted a observational in Heart failure-related cardiogenic shock (n=1,030). Acute-on-chronic heart failure vs. De novo heart failure was evaluated on 30-day mortality (adjusted HR 1.38, 95% CI 1.10-1.72, p=0.005). Acute-on-chronic heart failure-related cardiogenic shock had a higher 30-day mortality risk than de novo presentation (55.9% vs 45.5%; adjusted HR 1.38; 95% CI 1.10-1.72; p=0.005).